NeuroPace (NPCE) Stock Price, News & Analysis

Company Overview

NeuroPace, Inc. is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy. The system continuously records brain activity, detects abnormal electrical patterns that may lead to seizures, and delivers targeted stimulation to disrupt seizure activity before clinical symptoms arise. The RNS® System is implanted in the skull and connected directly to seizure foci via intracranial leads, offering a personalized therapy approach based on each patient’s unique seizure patterns.

NeuroPace holds regulatory approvals for the RNS® System in the United States and has obtained CE Mark certification for use in select European countries. The company works closely with leading epilepsy centers and neurosurgeons to support patient screening, surgical training, and postoperative programming. In addition to its clinical efforts, NeuroPace invests in ongoing research collaborations aimed at expanding closed-loop neuromodulation into other therapeutic areas, such as movement disorders and psychiatric conditions.

Guided by a leadership team with deep expertise in neurology, engineering and regulatory affairs, NeuroPace continues to refine its technology platform and explore new applications for responsive neurostimulation. The company maintains its headquarters in Silicon Valley and partners with hospitals, healthcare systems and academic institutions to enhance patient access and advance the scientific understanding of brain-responsive therapies.

Key Stats

• Today's Range: $15.47 to $16.20
• 50-Day Range: $12.84 to $19.29
• 52-Week Range: $7.56 to $19.60
• Volume: 96,174 shs
• Average Volume: 163,584 shs
• Market Capitalization: $544.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.83
• Consensus Rating: Moderate Buy

NeuroPace Stock Analysis - MarketRank™

NeuroPace scored higher than 60% of companies evaluated by MarketBeat, and ranked 328th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NeuroPace has a consensus price target of $18.83, representing about 18.0% upside from its current price of $15.96.

Amount of Analyst Coverage

NeuroPace has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroPace is -24.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroPace is -24.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroPace has a P/B Ratio of 28.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.15% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 3.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroPace has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroPace does not currently pay a dividend.

Dividend Growth

NeuroPace does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.73

News Sentiment

NeuroPace has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NeuroPace this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroPace insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/10/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NPCE
• CIK: 1528287
• Web: www.neuropace.com
• Phone: 650-237-2700
• Fax: N/A
• Employees: 170
• Year Founded: 1997

Price Target and Rating

• Average Price Target for NeuroPace: $18.83
• High Price Target: $22.00
• Low Price Target: $16.00
• Potential Upside/Downside: +18.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: -21.67%
• Pretax Margin: -21.67%
• Return on Equity: -108.20%
• Return on Assets: -18.50%

Debt

• Debt-to-Equity Ratio: 4.08
• Current Ratio: 5.38
• Quick Ratio: 4.35

Sales & Book Value

• Annual Sales: $99.99 million
• Price / Sales: 5.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 28.00

Miscellaneous

• Outstanding Shares: 34,090,000
• Free Float: 27,105,000
• Market Cap: $544.08 million
• Optionable: Optionable
• Beta: 1.88